Table 5.
CheckMate 040 dose-escalation cohort (n=48) baseline patient characteristics and prior treatment history
| Uninfected (n=23) | HCV (n=10) | HBV (n=15) | Total (n=48) | |
|---|---|---|---|---|
| Median age (range), years | 61 (22–79) | 67 (55–83) | 62 (41–75) | 62 (22–83) |
| ≥65 years, n (%) | 8 (35) | 6 (60) | 6 (40) | 20 (42) |
| Male, n (%) | 17 (74) | 6 (60) | 13 (87) | 36 (75) |
| Ethnicity, n (%) | ||||
| White | 19 (83) | 8 (80) | 1 (7) | 28 (58) |
| Asian | 2 (9) | 2 (17) | 14 (88) | 18 (38) |
| Black | 2 (9) | 0 | 0 | 2 (4) |
| Extrahepatic metastases, n (%) | 18 (78) | 6 (60) | 13 (87) | 37 (77) |
| Vascular invasion, n (%) | 3 (13) | 1 (10) | 2 (13) | 6 (13) |
| Child-Pugh score, n (%) | ||||
| 5 | 19 (83) | 8 (80) | 14 (93) | 41 (85) |
| 6 | 4 (17) | 2 (20) | 1 (7) | 7 (15) |
| α-Fetoprotein >200 μg/L, n (%) a | 8 (35) | 3 (30) | 8 (53) | 19 (40) |
| Prior treatment type, n (%) | ||||
| Surgical resection | 15 (65) | 8 (80) | 13 (87) | 36 (75) |
| Radiotherapy b (external or internal) | 6 (26) | 2 (20) | 2 (13) | 10 (21) |
| Local treatment for HCC c | 11 (48) | 8 (80) | 12 (80) | 31 (65) |
| Systemic therapy | 18 (78) | 6 (60) | 15 (100) | 39 (81) |
| Sorafenib | 16 (70) | 5 (50) | 14 (93) | 35 (73) |
a
Baseline α-fetoprotein values were missing for one uninfected patient;
b
Could include radioembolization;
c
TACE, RFA, or percutaneous ethanol injection. Reproduced with permission from El-Khoueiry AB, et al. [29]